# Tissue factor

Source: https://onco.cc/targets/tissue-factor/  
OnCo record `tissue-factor` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tissue factor is a clotting protein that cancers abnormally display on their surface, used as an ADC target in cervical cancer.

## Summary

Tissue factor (F3) initiates the extrinsic coagulation cascade; when cancers display it abnormally on their surface it drives thrombosis and angiogenesis, and it becomes an ADC target. It is overexpressed in cervical, pancreatic, head and neck, and ovarian tumours, with 90-95% of cervical and 50-80% of pancreatic cancers positive by IHC. Tisotumab vedotin (Tivdak) is approved in recurrent cervical cancer on the basis of innovaTV 301, and innovaTV did not select patients on tissue factor expression, so the drug is given without a companion test. Topoisomerase-I payload successors (XNW28012) are in phase 3. The open questions are ocular toxicity management and whether newer payloads widen the indication. The simple version is a clotting protein that cancers wear on their surface, letting an ADC find them.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target
- Symbol: F3
- Class: surface-antigen
- Biology: Initiates the extrinsic coagulation cascade; tumour expression drives thrombosis and angiogenesis.
- Where found: Cervical; Pancreatic; Head and neck; Ovarian

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Tissue_factor
- Wikipedia: https://en.wikipedia.org/wiki/Tissue_factor

## Connected records

- biomarkers: [Tissue factor expression](https://onco.cc/biomarkers/tissue-factor-expression/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Tisotumab vedotin](https://onco.cc/drugs/tisotumab-vedotin/)
- companies: [Adcendo](https://onco.cc/companies/adcendo/), [Sutro Biopharma](https://onco.cc/companies/sutro-biopharma/)
- trials: [innovaTV 301 / ENGOT-cx12 / GOG-3057](https://onco.cc/trials/innovatv-301/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- people: [Bradley J. Monk](https://onco.cc/people/bradley-monk/), [Ignace Vergote](https://onco.cc/people/ignace-vergote/)

---
JSON: https://onco.cc/api/v1/entities/tissue-factor.json